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Reviewa b s t r a c t
This digest covers some of the most relevant progress in malaria drug disco very published betwe en 2010 
and 2012. There is an urgent need to develop new antimalarial drugs. Such drugs can target the blood 
stage of the disease to alleviate the symptoms, the liver stag e to prevent relapses, and the transmission 
stage to protect other humans. The pipeline for the blood stag e is becoming robust, but this should not be 
a source of complacency, as the current therapies set a high standard. Drug disco very efforts directed 
towards the liver and transmission stages are in their infancy but are receiving increasing attention as 
targeting these stages could be instrumental in eradicating malaria. 
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.Malaria remains one of the most prevalent and deadly infec- 
tious diseases across Africa, Asia, and the Americas. The World 
Health Organizatio n (WHO) estimates 154–289 million malaria 
cases in 2010, with 660,000 associate d deaths. 1,2 An independen t
study suggests that the mortality is twice as high when including 
cases of malaria that are undiagnosed or untreated. 3 Eighty percent 
of the estimated cases occur in sub-Saharan Africa and 86% of 
deaths occur in children less than 5 years of age. 1 In Africa, the eco- 
nomic burden is estimated at $12 billion/year , but the sales of anti- 
malarial drugs are orders of magnitud e lower. 4 Advances in 
malaria research are often reviewed 2,5–16 and a recent mono- 
graph17 will prove useful to the medicinal chemist. This digest cov- 
ers some of the most relevant progress in malaria drug discovery 
from 2010 to 2012, and limits itself to compounds with EC 50 values
<100 nM in a parasite proliferation assay. We cover the blood 
stage, the liver stage, and the transmission stage of the disease. 
Each section contains several scaffolds, and within each scaffold 
the compounds are arranged, when possible, with the marketed 
drugs ﬁrst and the research compounds last. 
Several species of Plasmodium cause malaria in humans: Plas-
modium falciparum , Plasmodium vivax , Plasmodium ovale , Plasmo-
dium malariae and the simian Plasmodium knowlesi . The most 
lethal species is P. falciparum , found predomin antly in Africa. 18 If
left untreated, P. falciparum causes organ failures (severe malaria)
and accumulate s in the brain capillaries (cerebral malaria), leading to coma and eventually death. Furthermore, there is growing evi- 
dence that the lethality of P. vivax has been underestimate d. 19
The parasite has a complex life cycle and in order to eradicate 
the disease, every stage should be considered for treatment 
(Scheme 1):
1. Liver stage. Once the mosquito inoculates the parasites (spor-
ozoites) into the blood stream, the parasites invade the liver within 
30 min and start replicating there (schizonts). In addition, P. vivax 
and P. ovale can remain dormant in the liver (hypnozoites, not 
shown in Scheme 1) and cause relapses years after the initial infec- 
tion. Drugs that target the liver stages are important to prevent the 
disease from developing (prophylactic treatment) and to provide 
what is known as a ‘‘radical cure’’ for P. vivax and P. ovale .
2. Blood stage. After approximately 5–10 days, the liver cells 
burst and merozoites invade the red blood cells where they rapidly 
prolifera te, causing the symptom atic high fevers and the pathol- 
ogy. In their intraerythrocy tic phase, the merozoites go through 
various forms (rings, trophozoites, schizonts) to form an average 
of 20 daughter merozoites that are released into the bloodstream 
and infect new red blood cells. Drugs that target the blood stages 
are important to control the symptom s of the disease and associ- 
ated mortality. 
3. Transmission stage. After several cycles of asexual reproduc- 
tion, some parasites further different iate into male and female 
gametocyte s, which contain only a half set of chromosomes. 
4. Mosquito stage. When ingested by mosquitoes , the male and 
female gametocytes fuse in the midgut to form a zygote that fur- 
ther develops into new sporozoites ready for the next human 



















2: Dihydroartemisinin: R = H
3: Artemether: R = Me
4: Artesunate: R = -CO-CH2-CH2-CO2
-
EC50 = 3.1 nM (K1), ED50 = 6.2 mg/kg/day
5: Lumefantrine
EC50 = 0.45 nM (W2)














EC50 = 12.5 nM (W2)






EC50 = 20-23 nM (3D7)















EC50 = 19 nM (3D7), 49 nM (W2)
ED50 = 1.9-3.4 mg/kg/day
NEt2
Scheme 2. Current standard of care (artemisinin derivatives, combined with 
lumefantrine or piperaquine) and previous ﬁrst-line therapies (sulfadoxine–pyri-
methamine and chloroquine). In vitro potency data (EC50 values) are reported for 
proliferation assays using different strains of P. falciparum that are either drug- 
sensitive (3D7) or multi-drug resistant (Dd2, K1, W2). The in vivo efﬁcacy data 
(ED50 and ED 90 values) are reported for rodent models of malaria. Data are reported 
for artemisinin, 29 artesunate,29,30 lumefantrine,31,32 piperaquine,31,33 sulfadoxine,34
pyrimethamine,35,36 and chloroquine. 29,37,38
Scheme 1. Plasmodium life cycle. Liver, blood (= erythrocytic), transmission, and 
mosquito stages. See text for details. 
2830 M. A. Biamonte et al. / Bioorg. Med. Chem. Lett. 23 (2013) 2829–2843are important to prevent the infection of other humans, and would 
beneﬁt an eradication agenda. 
Artemisinin- based combination therapies (ACTs) are the cur- 
rent standard of care for uncompl icated malaria. Artemisinin (1,
Scheme 2) and its derivatives (2–4) have a fast onset of action 
but are cleared rapidly (human t1/2 1 h),21 and are therefore com- 
bined with slow-clearing drugs to kill residual parasites. Typical 
partner drugs include lumefantrin e (5, human t1/2 = 3–4 days)22
and piperaquine (6, human t1/2 = 8–16 days).23 The most popular 
combination consists of tablets containing artemether (3, 20 mg)
and lumefantrin e (5, 120 mg) sold as Coartem™ (Novartis).24
Adults take four tablets twice a day for 3 days, 25 but compliance 
to this six-dose regimen is variable. 26 In 2011, the European Med- 
icines Agency (EMA) approved the combination of dihydroarte mis- 
inin (2) and piperaquine (6) which is taken once a day for 3 days 
(Eurartesim™, Sigma-Tau).27 The ACTs have supplanted the previ- 
ously recommend ed sulfadoxine–pyrimethamine (7/8, Fansidar™,
Roche), which in turn replaced chloroquine (9). Parenteral artesu- 
nate (4) is the drug of choice for severe malaria. 28
For the liver stages, primaqui ne (10, Scheme 3) is the only drug 
approved to eliminate hypnozoites. As for prophylactic treatment, 
atovaquone –proguanil (11/12) (Malarone, GlaxoSmith Kline) is 
usually preferred because it is well tolerated, but is expensive. Inci- 
dentally, proguanil is a pro-drug , of which cycloguanil (13) is the 
active metabolite. For the transmission stages, primaquine (10) is 
the only registered drug active against the mature gametocyte .39
Resistance against the many existing antimalarial s is well doc- 
umented,45 and especially troubling is the emerging resistance to 
artemisinin s. 45–48 Combining drugs can limit the emergence of 
resistance, but this technique is not infallible . For instance, in parts 
of Cambodia, the proportion of patients who were still parasitemic 
after 3 days of treatment with the dihydroartemis inin–piperaquine 
combination increased from 26% in 2008 to 45% in 2010. 49 The
problem of drug resistance requires new drugs. The challenge is 
that drug resistance is not the only feature. New, innovative drugs 
should also (i) be fast acting, (ii) be safe for children and pregnant 
women, and (iii) ideally be amenable to a single-dose administra- 
tion. An example of how difﬁcult it is to combine all these features 
is seen in meﬂoquine. It is the only registered drug effective in asingle dose (14, Scheme 4, human t1/2 = 2–4 weeks, adult do- 
se = 1250 mg);50 however , drug resistance is problemati c. 51 Simi-
larly, the only marketed antimalarial drug combination effective 
as a single dose is sulfadoxine–pyrimethamine, but it also suffers 
from drug resistance. 45,52,53
Artemisini n is commerc ially produced by extraction from sweet 
wormwood (Artemisia annua ) at a cost of $400–1100/kg. A recent 
alternativ e production method involves a yeast fermentation pro- 
cess that delivers the biosynthetic precursor artemisinic acid (15,
Scheme 5, Amyris). The latter is converted to artemisinin in 62% 
yield using a photochemical oxidation process being impleme nted 
by Sanoﬁ.54 An independent group adapted the process to a contin- 
uous ﬂow reactor, better suited for conducting photoche mistry at 
an industrial scale, thus potential ly reducing production costs. 55
In addition, Zhu and Cook published a remarkably concise synthe- 













EC50 = 0.53 nM (W2)
ED50 = 0.07 mg/kg/day
12: Proguanil
















EC50 = 38 nM
ED90 = 3.7 mg/kg/day
Scheme 3. Preferred drugs for the elimination of hypnozoites (primaquine),
preferred combination for prophylaxis (atovaquone–proguanil), and the active 
metabolite of proguanil (cycloguanil). Data are reported for primaquine, 40 ato- 




EC50 = 7 nM (W2)






Scheme 4. Meﬂoquine, the only single-agent antimalarial active as a single-dose in 
human. The EC 50 value is for the multi-drug resistant strain W2, and the ED 50 data 
for a single p.o. administration to mice. 201 Meﬂoquine is a racemate, and the 











































EC50 = 0.88 nM (3D7)







































Scheme 6. Active ingredients used in combinations that have potential for single- 
dose cure. EC 50 values are reported for the drug-sensitive strains 3D7 and NF54. 
M. A. Biamonte et al. / Bioorg. Med. Chem. Lett. 23 (2013) 2829–2843 2831ﬁve pots to the desired product, thus challenging the paradigm 
that total synthesis is not amenable to an industrially viable 
process.56
The combinati on of an artemisinin derivative with slow-clear- 
ing drugs can cure malaria in a single dose. The combination of artemisin in (1000 mg) and naphthoq uine (17, Scheme 6, 400 mg)
introduce d by the Chinese army, appears to be effective as a single 
dose of eight tablets (ARCO, Phase III).57–63 Artemisone (18), a drug 
in Phase II trials, is 10 times more potent than artesunate (4)
in vitro 64 and 4–10 times more potent in mice. 64 It provides a sin- 
gle-dose cure in Aotus monkeys infected with P. falciparum at
10 mg/kg when combined with meﬂoquine (5 mg/kg).65 Artemi-
sone is also active in a murine model of cerebral malaria. 66 Com-
bining artemisinin derivatives 1932 or 2067 (6 or 30 mg/kg, 
respectively ) with the longer-actin g meﬂoquine hydrochlori de 
(18 mg/kg) was found to be curative in a single dose. 
The antimala rial action of artemisin in is thought to involve the 
cleavage of the peroxide bond by Fe(II) found in heme proteins, 
thus generating toxic oxygen radicals. Synthetic peroxides are 
proving to be useful substitut es for artemisinin . The ﬁrst-genera-
tion ozonide OZ277 (21, Scheme 7), known as arterolane, inhibits 
the growth of chloroqui ne-resistant (K1) and chloroquine-se nsitive 
(NF54) parasite strains with an IC 50 = 1.6–1.8 nM. 68 In 2012, Ranb- 
axy launched the combination of arterolan e maleate and piperaq- 
uine phosphate as a 3-day treatment in India. 
The second-generati on peroxide OZ439 (22, Scheme 7)
(EC50 = 3.4–4.0 nM) is now in Phase IIa studies. It features an 80-
aryl rather than an 80-alkyl group. 30 This seemingly inconspicuous 
modiﬁcation has far-reaching consequences . The stability of the O–
O bond towards Fe(II) increases by 50-fold, presumably because of 
steric reasons. This in turn translates into a much longer half-life in 
both rats (t1/2 = 20 h for OZ439 vs. 1 h for OZ277) and humans (t1/
2 = 25–30 h for OZ439).30,69 The improved pharmacokine tic proﬁle
renders OZ439 capable of completely curing mice of malaria in a
single dose of 20 mg/kg, a feat that artemisinin derivatives cannot 
achieve without the addition of a second drug. Furthermore, OZ439 
has signiﬁcant prophyla ctic activity, and a single 30 mg/kg oral 
dose of OZ439 administere d 48 h prior to parasite inoculation is 
protectiv e. In rat, multiple doses of OZ439 are tolerated up to 
300 mg/kg. 30 These ozonides are synthesized from an oxime (23)














































Scheme 7. The ozonides OZ277 (Arterolane) and OZ439. 
2832 M. A. Biamonte et al. / Bioorg. Med. Chem. Lett. 23 (2013) 2829–2843Another way of stabilizing the O–O bond is to form tetraoxanes, 
as was employed in the drug developmen t candidat e RKA 182 (26,
Scheme 8),70 which displays IC 50 values of 4.9 nM against the P. fal- 
ciparum 3D7 strain and of 1.9 nM against the K1 strain (chloro-
quine-sensiti ve and -resistant, respectively ). In a mouse model of 
malaria, RKA 182 inhibits parasite growth with an ED 50 of
1.8 mg/kg/da y. The oral bioavailability of its tosylate salt is 42% 
in mouse and 38% in rat. The tetraoxane ring is made via a
Re2O7-catalyzed step (27?28).70 RKA 182 is not curative in a single 
dose.
The Central Drug Research Institute, Lucknow, India, is investi- 
gating the trioxane CDRI-97/78 (29, Scheme 9) in Phase I stud- 
ies.71–73 The key step in the construction of the trioxane core is 
an ene reaction between an allylic alcohol (30) and singlet oxygen, 
to give peroxide 31. Additional artemisin in derivatives, 74 ozo-
nides,75 and 1,2,4-trioxa nes 72,76 have been reported to have poten- 
cies compara ble to artemether, but were not shown to possess 
obvious advantages. 
The prototypical 4-aminoq uinoline chloroquine has been 
widely used for treating malaria since World War II. Chloroquine 26: RKA 182
EC50 = 1. 9nM (3D7)


















Scheme 8. The tetraoxane RKA182. EC 50 values are reported for the drug-sensitive 
strain 3D7. exerts its antimala rial action by interfering with the formation of 
hemozoin within the parasite’s digestive vacuole. Hemozoin is a
crystalline derivative of heme that the parasite makes as a way 
of disposing of toxic heme released upon hemoglobin digestion. 
Resistance to chloroquine is now found in all areas of the world, 
and involves multiple mutations in the P. falciparum chloroquine
resistance transporter , PfCRT. These mutations result in an in- 
creased efﬂux of chloroquine from the acidic digestive vacuole to 
the cytosol of the parasite. Ferroquine (33, Scheme 10 ) was found 
to be active against chloroquine- resistant strains, and is currently 
undergoi ng Phase II clinical trials. Ferroquine, unlike chloroquine, 
accumulate s in the digestive vacuole of the chloroquine-re sistant 
parasites . This was demonstrat ed by X-ray ﬂuorescence micros- 
copy, a technique that allows visualizing the chlorine atom of both 
drugs.77 It was also shown that replacing the expensive ferrocene 
moiety of ferroquin e with a simple and inexpensive benzene ring 
as in 34 and 35 retains activity against chloroquine-re sistant 
strains (K1, W2).78 Because of its basicity, 35 is expected to accu- 
mulate like other 4-aminoqui nolines in the acidic (pH = 5) environ- 
ment of the food vacuole. In this organelle , the concentration of 35
is calculated to reach 370 lM at pharmacolo gically relevant doses, 
thus enabling PfCRT inhibition (IC50 = 69 lM) to become an opera- 
tional second mode of action. 79 The fused ‘dimeric quinoline’ 36 is
active in vitro against drug-resistant strains, and in mouse when 
administ ered orally at 80 mg/kg. 80
Amodiaqui ne (37, Scheme 11 ) is also active against most chlo- 
roquine- resistant strains; however, hepatitis, myelotoxi city and 
agranulocy tosis restrict its use to treating acute malaria. Amodia- 
quine is rapidly absorbed after oral administrat ion in human, and 
rapidly metaboli zed, mostly, via N-deethylati on. In addition, two 
reactive metaboli tes are formed, namely imine 38 and aldehyde 
39, and are the likely cause of the hepatotoxicity and agranulocy- 
tosis, respectively .
N-tert-Butyl isoquine (GSK369796, 40, Scheme 11 ) was de- 
signed to avoid the formatio n of quinone imines, and entered 
Phase I studies. It is potent in vitro, including in the chloroquine- 
resistant strain K1 (EC50 = 13 nM) and is active in vivo with an 
ED50 = 3.8 mg/kg/day, thus being comparable to amodia- 
quine.38,81,82 In spite of the excellent exposures and near quantita- 
tive oral bioavailabili ties in animal models, its developmen t was 
discontinue d due to exposures insufﬁcient to demonstrate drug 
safety superior to chloroquine. 17
Analogs exempliﬁed by 41 (Scheme 11 ) were also designed to 
prevent the formation of quinone imines, and were found to retain 
activity against chloroquine-re sistant strains. 83
Meﬂoquine (14, Scheme 12 ) has been widely used for malaria 
preventio n due to a long half-life (2–4 weeks in human) that 
necessita tes only a once-we ekly dosing. Meﬂoquine is sold as a
racemate (Lariam), and causes a relatively high incidence of 









EC50 = 19 nM (3D7), 49 nM (W2)
33: Ferroquine
EC50 = 6.6 ± 0.9 nM (W2)
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34: R = H: EC50 = 6.9 nM (K1)























































EC50 = 11 nM (W2)
11
12 HN
Scheme 12. 4-Hydroxymethylquinolines. Note that meﬂoquine is a racemate, and 
the reported stereochemistry for meﬂoquine is relative, not absolute. EC 50 values 











40: N-tert -butyl isoquine 
EC50 = 11 nM (3D7)







EC50 = 11 nM (3D7)
















Scheme 11. Amodiaquine and derivatives. EC 50 values are reported for the drug- 
sensitive strain 3D7 and the multi-drug resistant strains W2. 
M. A. Biamonte et al. / Bioorg. Med. Chem. Lett. 23 (2013) 2829–2843 2833are active, the ()-enantiomer 42 is believed to cause the neuro- 
logical side effects by binding the adenosine receptors in the 
brain.84 In an effort to select the next generation of quinoline 
methanol derivatives that could serve as a replacemen t for meﬂo-
quine, the Walter Reed Army Institute of Research screened for 
analogs with a lower brain penetrati on, and identiﬁed WR621308 
(44).85,86 WR6213 08 has a substantially lower permeabilit y across 
MDCK cell monolayers than meﬂoquine, suggesting lower brain 
exposures.
Some of the most important malaria drugs, cycloguanil (13) and 
pyrimetham ine (8), are inhibitors of dihydrofola te reductase 
(DHFR). DHFR converts 7,8-dihydro folate (45, Scheme 13 ) into tet- 
rahydrofolate (46), a cofactor involved in one-carbon transfer reac- 
tions and in the biosynthesis of nucleic acids. Inhibition of DHFR 
therefore arrests DNA replicatio n, 87 but resistance is widespread 
due to mutations in the enzyme. 
Structure-bas ed drug design resulted in P218 (48, Scheme 13 ), a
DHFR inhibitor active against all clinically relevant mutations. 88
P218 combines the pyrimidine ring of pyrimeth amine (8,
Scheme 13 ), which brings potency, and the linker of the DHFR 
inhibitor WR99210 (47, Scheme 13 ), which tolerates mutations 
due to its ﬂexibility. Furthermore, the terminal carboxylate group forms a salt bridge to the conserved Arg122 residue, thus mimick- 
ing the a-carboxylate of dihydrofola te (45). P218 is more potent 
than pyrimeth amine against DHFR in the wild-type strain TM4 
(IC50 = 4.6 and 58 nM, respectively ) as well as in the quadruple mu- 
tant strain V1/S (IC50 = 56 and >100,000 nM, respectively ). P218 is 
active against quadruple mutant P. falciparum in mice, with an 
ED50 = 0.3 mg/kg/day, orally. In rat, the oral bioavailabili ty is 46%, 
and the oral t1/2 is 7.3 h. 88
About 125 million pregnancies are at risk of malaria every year, 
and 10,000 women and 200,000 babies die as a result. An intermit- 
tent preventative treatment (IPT) is recommend ed for pregnant 
women, but drug-resistanc e to the currently adopted IPT (sulfa-
doxine–pyrimethamine ) necessitates new and effective regimens. 
Both azithromycin (49, Scheme 14 ) and chloroquine have demon- 
strated safety in children and pregnant women over a number of 
years. Notably, the azithromycin–chloroquine combination is de- 
signed to be synergist ic against chloroquine- resistant strains of P.
falciparum,89 and was shown to be synergistic in the treatment of 






















EC50 = 0.7 nM (3D7)
ED50 = 1.2 mg/kg
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2834 M. A. Biamonte et al. / Bioorg. Med. Chem. Lett. 23 (2013) 2829–2843a slow-acting antimalarial, with a maximum antiparasi tic effect 
occurring only after two cycles of intraerythr ocytic developmen t
(one cycle of invasion, developmen t, and egress lasts 42–
48 h).89,90 Finding azithromycin analogs with improved activity 
in mouse models of malaria has been challenging. 90–92
The Novartis team screened its compound collection, identiﬁed
spiroindolones as a novel chemotyp e, and optimized the series to 
deliver NITD-609 (52, Scheme 15 ), now in Phase II trials. 29 The tar- 
get was identiﬁed by genomics using clones with decreased sus- 
ceptibility and was found to be the cation channel PfATPase4. 29
In the medicinal chemistry route, the two enantiomers were sepa- 
rated by chiral chromatography .93 NITD-609 has an excellent po- 
tency, with EC 50 = 0.7 nM (3D7) and is 100% orally bioavailable in 
mouse and rat. Its oral t1/2 is 10 h (mouse) and 27 h (rat). In mouse, 
NITD-609 has an ED 50 = 1.2 mg/kg, and is thus more potent than 
artesunate (ED50 = 6.2 mg/kg) or chloroquine (ED50 = 1.9 mg/kg).
Three daily doses of 50 mg/kg, or a single dose of 100 mg/kg, affor- 
ded a complete cure. NITD-609 is also a potent inhibitor of gameto- 
cytogenesis , and blocks transmis sion to mosquitoes .94 The
Medicines for Malaria Ventures (MMV) selected the spiroindolone 
project6,7 as the Project of the Year 2009. Albitiazol ium (54, Scheme 16 , also known as T3 or SAR97276) is 
a drug that has reached Phase II clinical trials (CNRS/University of 
Montpell ier/Sanoﬁ).95 The understand ing of its mechanis m has re- 
cently been reﬁned.96,97 Albitiazoliu m acts primarily by inhibiting 
the transport of choline into the parasite. 97 The parasite requires 
choline to generate phosphatidylch oline (53), the main lipid of 
its cell membranes , as it replicates and forms new membranes .
An important property of albitiazo lium is that it accumulates irre- 
versibly in the Plasmodium up to 1000-fold. Albitiazol ium inhibits 
parasite growth (EC50 = 2 nM) and cures mice with an 
ED50 = 0.2 mg/kg/day (ip) without recrudescence. It is also active 
in severe condition s (ED50 60.5 mg/kg ip at 5–10% parasitemia).
Notably, a single injection is curative (ED50 = 1 mg/kg ip at 0.5–
1% parasitemia ). A single-dose cure is observed even at high para- 
sitemia levels (ED50 = 2.5 mg/kg ip at 5–10% parasitemia).98,99
Albitiazol ium is also efﬁcacious when given orally, but with a
much lower ED 50 = 13 mg/kg/day, 100 suggesting an oral bioavail- 
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EC50 = 7 nM (3D7)












EC50 = 1100 nM (3D7)












EC50 = 43 nM (3D7)












































EC50 = 28 nM (3D7 strain)
EC50 = 65 nM (Dd2 strain)


















EC50 = 0.54 nM (Dd2)
Erythrocyte lysis > 40 µM
Scheme 18. New scaffolds from phenotypic screens. EC 50 values are reported for 
the drug-sensitive strain 3D7 and the multi-drug resistant strain Dd2. 
M. A. Biamonte et al. / Bioorg. Med. Chem. Lett. 23 (2013) 2829–2843 2835ability, the clinical trials have been conducted with intravenous or 
intramuscu lar injections. An oral version of albitiazolium would be 
highly desirable. The pro-drug TE3, reported in 2004–2005, has an 
oral ED 50 = 5 mg/kg/day. 98,101 This indicates a 2–3-fold improve- 
ment in mouse oral bioavaila bility; the rat bioavailability is 
15%.100 In spite of numerous efforts made in the last few 
years,37,102–105 the bioavailabili ty of these bis-cations has not been 
improved yet. 
Unlike its human host, P. falciparum cannot salvage pyrimidines ,
and therefore depends on their de novo biosynthesis. Dihydroo ro- 
tate dehydrogenase (DHODH) is the enzyme which catalyzes the 
rate-limiting step of the de novo pyrimidine biosynthetic pathway 
(56?59, Scheme 17 ). Factors that affect the human versus Plasmo-
dium DHODH selectivity have been investigated by crystallogra- 
phy.106 The DHODH approach was awarded the MMV Project of 
the Year 2010. 
A project coordinated by the MMV and involving the University 
of Texas Southwester n, the University of Washington , Monash Uni- 
versity, and GlaxoSmithKline reported the preclinical candidate 
DSM265 (60, Scheme 17 ), expected to enter Phase I studies in 
2013.107 DSM265 inhibits PfDHODH selectively over its human 
counterpart (IC50 = 33 nM and 2500 nM, respectivel y). It is orally 
bioavailable (rat: F = 57–68%, t1/2 = 12–28 h), and efﬁcacious
in vitro (EC50 = 43 nM (3D7)) and in mouse (ED50 = 2.8 mg/kg/ 
day). A related effort identiﬁed triazolopyrim idine DSM190 (61,
Scheme 17 ), which is less potent in vitro (IC50 = 190 nM, 
EC50 = 1.1 lM (3D7)) and in mouse (ED50 = 10 mg/kg/day), but 
has a bioavailability of 100% in rat. 36
Genzyme reported DHODH inhibitor 62 (Scheme 17 ) as a poten- 
tial drug development candidate. 108 Benzimidaz ole 62 inhibits
PfDHODH (IC50 = 40 nM) and parasite growth (EC50 = 7–10 nM, 
3D7, Dd2). It is bioavailable in rat (49%) and dog (19%) and is elim- 
inated with t1/2 = 0.85 h (rat) or 0.52 h (dog). In mouse, it is efﬁca-
cious with an ED 50 of 13 mg/kg/da y. 108
Most efforts use high-throughp ut phenotypic screens against 
the blood stage. GlaxoSmith Kline, 109 Novartis,110 and the St. Jude 
Children’s Research Hospital 111 performed such screens and made 
20,000 hits publically available . The MMV narrowed the list down 
to 400 compounds representing a diverse dataset with low toxicity. 
The resulting ‘‘Malaria Box’’ can be download ed, and is available in 
plates from the MMV. The targets are not known and will require 
deconvolution .112,113 Additional screens are reported below and a
recent review of the patent literature is also available. 114Screening 70,000 compounds from the Broad Institute and the 
Harvard Medical School against the chloroquine resistant strain 
Dd2 led to Genzyme’s Genz-668764 (63, Scheme 18 , single enan- 
tiomer, absolute conﬁguration not published).115 Genz-668764
inhibits P. falciparum in vitro (EC50 = 28 and 65 nM, 3D7 and Dd2 
strains, respectivel y) and is active in mouse at doses of the order 
of 100 mg/kg/da y. Allometric scaling predicts a human dose of 
6 mg/day qd for 3 days, which would maintain plasma trough lev- 
2836 M. A. Biamonte et al. / Bioorg. Med. Chem. Lett. 23 (2013) 2829–2843els above the EC 50 against P. falciparum for at least 96 h after the 
last dose. The predicted human therapeutic index is approximat ely 
3, on the basis of the exposure in rats at the no observable adverse 
effect level (NOAEL).
A similar screen of the 8000 compounds from the Broad Insti- 
tute’s diversity-orien ted synthesis (DOS) library led to the discov- 
ery of the extremely potent ML238 (64, Scheme 18 , EC 50 = 0.5 nM 
(Dd2)), which is also highly water soluble (120 lM) and not 
cytotoxic.116
Actelion reported ACT-213615 (65, Scheme 19 ).117,118 The com- 
pound is fast-acting against all asexual erythrocytic stages. 
Although 30 times less potent against the murine Plasmodiu m berg- 
hei than against P. falciparum , ACT-213615 complete ly cured P.
berghei-infected mice with three consecutive oral daily doses of 
750 mg/kg (ED90 = 54 mg/kg/day). ACT-213615 was efﬁcacious in 
the recently established SCID mouse P. falciparum model
(ED90 = 8.4 mg/kg/day) with potencies comparable to chloroquine 
(ED90 = 6.4 mg/kg/day). No acute toxicity was observed. 
Anacor119 identiﬁed benzoxabor ole (66, Scheme 19 , EC 50 = 26–
44 nM) as a promising starting point (MW = 206, low clogP, solu- 
bility: 750 lg/mL at pH 7, and low to no cytotoxicity).120,121 SAR
studies suggested that an acidic side-chain is favored for high 
anti-malaria l potency, and a number of compounds with EC 50 val-
ues <100 nM were discovered, such as 67. Further optimizati on is 
ongoing.
The screening network funded by the WHO Special Programme 
for Research and Training in Tropical Diseases (TDR) reported the 
results of a 10,000 compound screen against seven whole organism 
pathogens responsible for tropical diseases, including the intra- 
erythrocytic forms of P. falciparum .122 The most potent screening 
hit was TDR84420 (68, Scheme 19 ) with an EC 50 = 326 nM (K1).
The publicall y available screening data set from GSK has been 
analyzed to extract SAR trends 123 and GSK identiﬁed 47 high qual- 
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Scheme 19. New scaffolds from phenotypic screens (continued). EC 50 values are 
reported for the drug-sensitive strain NF54 and the multi-drug resistant strain K1. led to the selection of ﬁve series. One of them was deprioriti zed 
due to resistance issues. TCMDC-134 142 (69, Scheme 19 ) repre- 
sents one of the four remaining series. 125
Amongst the targeted approaches, kinase inhibitors have been 
evaluated but so far are weak inhibitors (EC50 >100 nM)8,126 and
are therefore outside of the scope of this digest. 
GSK reported a series of highly potent 2-pyrimi dinecarbonitr- 
iles as inhibitors of falcipain-2 and falcipain-3, such as 70
(Scheme 20 , EC 50 = 1 nM).127 Falcipains are cysteine proteases that 
hydrolyz e the host hemoglobin to provide amino acids for parasite 
protein synthesis. 
Harmine (71, Scheme 20 ) was reported to inhibit the Plasmo-
dium heat shock protein 90 (Hsp90) and some selectivity over 
the human Hsp90 was observed. Its cellular activity is 
EC50 = 50 nM (3D7).128 Hsp90 inhibitors have traditionally been 
pursued for cancer, and were found to have a limited therapeutic 
window.129
Epigeneti c factors regulate the progression of the malaria para- 
site through its complex life cycle, and malarial histone acetyl- 
transfera se (HAT)130 and histone deacetylase (HDAC)131,132
inhibitors have been reported. Recently, the targeting of P. falcipa- 
rum epigeneti c factors was extended to include inhibitors of his- 
tone methyltransfer ases, such as BIX-01294 133 and TM2-115 (72/
73, Scheme 20 ).134 In an acute infection mouse model (highly vir- 
ulent P. berghei ANKA strain), the compounds (dosed ip, 40 mg/kg)
showed a rapid onset and a 2- and 18-fold parasite reduction. 
Febrifugine (74, Scheme 21 ) is the active component of the Chi- 
nese herb Chang Shan (Dichroa febrifuga ), and is an appealing anti- 
malarial because of its rapid effect and availability. However, 
strong liver toxicity has precluded its use as a clinical drug. Radix 
Pharmaceut icals discovered febrifugine analog 75 with a much im- 
proved therapeutic index in mouse (TI = 132 vs 3), thus exceeding 
the therapeutic index of artesunate (TI = 37).135 The therapeutic in- 
dex was deﬁned as the ratio between the maximum tolerated dose 
(MTD), and the minimum clearance dose (MCD). Compound 75 is
effective in mouse (EC50 = 0.3 mg/kg/day) and in Aotus monkeys
(EC50 = 2 mg/kg/day).135
Several additional active compound s were identiﬁed by various 
approach es (Scheme 22 ), including the potent marine natural 
product salinospora mide A (74),136 SSJ-183 (75),137,138 prodiginine









Histone methyl transferase inhibitors
72: BIX-01294 (R1 = Me, R2 = Bn)
EC50 = 75 nM (3D7)
73: TM2-115 (R1 = Bn, R2 = Me)
















IC50 < 0.5 nM





71: Harmine, PfHsp90 Inhibitor
EC50 = 50 nM (3D7)
Scheme 20. New scaffolds from targeted approaches. EC 50 values are reported for 
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74: Salinosporamide A
EC50 = 11 nM










Scheme 22. New scaffolds from various approaches. EC 50 values are reported for 







EC50 = 2.1 nM (Dd2)
ED50 = 2.3 mg/kg/day
MCD = 12 mg/kg/day








EC50 = 0.26 nM (Dd2)
ED50 = 0.31 mg/kg/day
MCD = 1.9 mg/kg/day
MTD = 250 mg/kg/day
TI = 132
Scheme 21. Febrifugine and improved analog. MCD = minimum clearance dose. 
MTD = maximum tolerated dose. TI = therapeutic index = MTD/MCD. EC 50 values 
are reported for the multi-drug resistant strain Dd2. 
M. A. Biamonte et al. / Bioorg. Med. Chem. Lett. 23 (2013) 2829–2843 2837dolone 79,142 propafenone 80,143 sulfonamide 81,144 diamine
82,145 the iridoid 83 extracted from traditional African herbal rem- 
edies,146 and iThemba’s 84.147
Currently, most approved malaria drugs target only the blood 
stages of the disease. The two exceptions are the combinati on of 
atovaquone /proguanil which is also effective in clearing parasites 
from the liver, and primaquine. 148 The latter clears not only liver 
schizonts but also hypnozoites , the dormant liver-stage parasites 
in P. vivax and P. ovale infections, thus providing what is known 
as a radical cure. 149 Hypnozoites are long-lasting reservoirs 
responsible for recurring malaria episodes in the absence of mos- 
quito bites, and are a major health concern, especiall y in the case 
of P. vivax .
The search for liver stage drugs has been severely hampere d by 
the lack of culture techniqu es and by cumbersom e primate animal 
models. It has been suggested that for prophylacti c treatment, 
compounds without blood stage activity might be preferred in or- 
der to minimize the risk of the emergence of drug-resistant 
parasites.
Primaquine is a drug that acts slowly, 150 and is therefore given 
together with other drugs, for example, chloroqui ne. Its mecha- 
nism of action is unclear, but is believed to be mediated by reactive 
metabolites which destroy the mitochondrial structure of the par- 
asite. Primaquine, however , causes hemolytic anemia in people 
with glucose-6 -phosphate dehydrogen ase (G6PD) deﬁciencies,
which occur in 10% of the population, 151 and are particular ly pre- 
valent in malaria endemic countries. 202 In fact, the spatial extent of 
P. vivax malaria overlaps widely with that of G6PD deﬁciency.202
Additionally , compliance with the primaquine 14-day treatment 
regimen is difﬁcult.
The primaquine analog tafenoquine (85, Scheme 23 ) is cur- 
rently in Phase IIb/III clinical trials and has proven activity against 
hypnozoites . Tafenoquine has the same G6PD deﬁciency liability as 
primaquine, but has the advantag e of being a single-dose 
treatment.
Recent drug discovery efforts have focused speciﬁcally on tar- 
geting the asymptomati c liver stage sporozoites and/or hypnozo- 
ites (possibly in addition to the blood stages) in order to provide 
novel, non-8-aminoqui noline drugs without the G6PD liabil- 
ity.149,152,153 A new imaging techniqu e of Plasmodium liver stages, 
described by The Scripps Research Institute and Novartis, consti- 
tutes a breakthr ough, and was applied to prioritize 4000 com- 
pounds already possessing blood-stage activity. 154
Imidazolopi perazines emerged as a hit series, exempliﬁed by 
GNF-Pf-5069 (86, Scheme 24 ), which was then optimized to pro- 
vide GNF179 (87) and GNF156 (88). The latter is currently in Phase 
I clinical trials. 155,156
Most data was initially reported for the nonclinical compound 
GNF179,155 which inhibits both the blood stages of P. falciparum 
(EC50 = 6 nM (3D7)) and the liver stages of the murine Plasmodiumyoelii, (EC50 = 5 nM). GNF179 is orally bioavailable in mouse 
(F = 58%, t1/2 = 8.9 h), and reduces P. berghei parasitemia in mice 
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EC50 = 462 nM (3D7)
EC50 = 221 nM (P.yoelii liver stage)
Poor exposure in animal models
87: GNF179 (R = Cl)
EC50 = 6 nM (3D7)
EC50 = ~5 nM (P.yoelii liver stages)
hERG (binding) IC50 = 6.6 µM









88: GNF156 (R = F)
EC50 = 6 nM (3D7 strain)
EC50 = N/A (P.yoelii liver stages)
hERG (binding) IC50 = 6.6 µM
ED99 = 2.2 mg/kg
Scheme 24. Imidazolopiperazines. EC 50 values are reported for the drug-sensitive 









90: R = CH2OH
EC50 = 2 nM
ED50 = 0.6 mg/kg/day
F = 50%
89: GW844520, R = Me
EC50 = 7 nM



















EC50 = 83 nM








IC50 = 15 nM (PfNDH2)
EC50 = 54 nM (3D7)
















EC50 ~ 2.6 nM (liver stages)
Scheme 25. Pyridones with activity against liver stages. EC 50 values are reported 
for the drug-sensitive strain 3D7 and multi-drug resistant strain W2. 
2838 M. A. Biamonte et al. / Bioorg. Med. Chem. Lett. 23 (2013) 2829–2843GNF179 was shown to be completely protective in mice challenged 
with P. berghei sporozoites.
GNF156 was recently shown to be equally as potent as GNF179 
against P. falciparum (EC50 = 6 nM (3D7)). The potency against P.
yoelii liver stages has not been disclosed. 156 GNF156 is orally bio- 
available in mouse (F = 72%, t1/2 = 2.2 h) and rat (F = 20–57%, t1/
2 = 4.7–8.4 h).156 It is notewort hy that GNF156 not only inhibits 
the liver stages, but also transmission. 156b
It is not yet known whether these compounds are active against 
the hypnozoites of P. vivax and P. ovale and would thus be able to 
provide a radical cure. 154 The mechanism of action of the imidaz- 
olopiperazin es remains unknown. 
Atovaquone (11) targets the electron transport chain (ECT) of 
the mitochondrion , and speciﬁcally the cytochrome bc1 complex.
Additional quinones have been reported, without obvious advan- 
tage,157,158 and most progress was made with pyridones. 
GSK reported a back-up to pyridone GW844520 (89,
Scheme 25 ), a molecule targeting cytochrome bc1; hydroxyme thyl 
derivative 90 remarkably improved the mouse oral bioavailability 
(50%) as compared to GW844520 (20%).159
The paucity of compounds with anti-relapse properties led to 
the reinvestigat ion of the quinolone ICI 56,780 (91, Scheme 25 ).
The latter was discovered in the 1960s and a 7-day regimen of 
91 prevents relapses for 120 days in rhesus monkeys infected with Plasmodiu m cynomolgi , suggestin g potency against hypnozoites . It 
was abandon ed because resistance was obtained after only a single 
passage in P. berghei infected mice. The group of Manetsch at the 
Universit y of South Florida, reported compound 92 with an 
EC50 = 28 nM against the W2 strain, and of 31 nM against the ato- 
vaquone- resistant TM90-C2B strain (chloroquine-, meﬂoquine-, 
pyrimeth amine-, and atovaquone -resistant).41,160,161 The Guy 
group at St. Jude Children’s Research Hospital, Memphis, reported 
compound 93 with an EC 50 = 83 nM, 162 which has suppression 
activity in mice compara ble to that of amodiaq uine (57% suppres- 
sion of parasitemia at 30 mg/kg) but is not curative. It remains to 
be investiga ted if activity against hypnozoi tes is maintained , and 
if resistance against 92 and 93 develops as fast as with ICI 56,780. 
In a screen including 1037 compounds which have reached at 
least Phase I clinical trials (veterinary and/or human), decoquinate 
(94, Scheme 25 ), an approved veterinary drug, was identiﬁed to po- 
tently inhibit the P. yoelii liver stage (estimated EC 50 of 2.6 nM) as 
well as the asexual (EC50 = 10 nM) and sexual (EC50 = 36 nM) P. fal- 
ciparum blood stages. 163 The decoquinate-ind uced reduction of 
mosquito transmission has not been reported. Decoquinat e
(administered p.o., 10 mg/kg) was found to completely protect P.
berghei infected mice from developing disease when treated 24 h
after the infection. The molecular target is the parasitic cyto- 
chrome bc1 complex (IC50 = 2 nM, >5000-fold selectivity over its 
human counterpar t).164 Unfortunate ly, decoquinate has so far only 
been tested in animals, which makes the repurposing of this drug 
challengi ng. 
The O’Neill group, at the Universit y of Liverpool, searched for 
compound s that would inhibit another enzyme involved in the 
ECT, namely NADH:ubiq uinone reductase (PfNDH2). A succession 
of in silico screens, HTS, and medicinal chemistry activities led to 
CK-2-25 (95, Scheme 25 ), which is speciﬁc for PfNDH2 over bc1,
and is potent in mouse, with an ED 50 = 1.8 mg/kg. 42,165
M. A. Biamonte et al. / Bioorg. Med. Chem. Lett. 23 (2013) 2829–2843 2839The ﬁrst screening examples have been reported, such as the 
imidazolopip erazines 86–88 described above. 154 Additionally, a
set of 5300 biologically active compounds , which included 640 
FDA-approved drugs, was screened and 37 structurally diverse 
compounds with varied known biologica l functions were identiﬁed
to also inhibit the malarial liver stages. 166 Screening a natural 
product library highlighted the secondary fungal metaboli te clado- 
sporin (96, Scheme 26 ), which potently inhibits the blood and liver 
stages in drug sensitive and multiple drug-resistant cell lines (IC50
40–90 nM).167 The molecular target was identiﬁed to be cyto- 
plasmic lysyl-tRNA synthetas e. (PfKrs1) Cladosporin is selective 
over human Krs1 (IC50 >20 lM).
In addition, there is a growing interest in signal peptide pepti- 
dases (SPP) such as NITD-731 (97, Scheme 26 ) which inhibits P.
yoelii liver stages with EC 50 = 7.8 nM. 168
Since many different proteins are expressed during the liver and 
blood stages of the parasite’s life cycle 169,170 and since the neces- 
sary medium- to high-thro ughput liver stages assays are continu- 
ously being developed and reﬁned including assays which allow 
the assessment of hypnozoi ticidal activities, 171–174 it is reasonabl e
to believe that in the near future many new chemotypes and bio- 
logical targets will emerge from these efforts. 
Drugs that can reduce the formation of gametocyte s (gametocy- 
togenesis), or can kill them (gametocytocides), are highly desirable 
but have been underexplor ed because of the lack of quantitative 
high throughput assays. 175,176 These transmission-bl ocking drugs 
could target endpoint s such as: 
(1) The effective and complete killing of mature gametocytes 
once they are formed in the human host. 
(2) The inhibition of the onward developmen t of gametocytes 
into ookinetes and ultimately into sporozoites in the mos- 
quito. This assumes that enough drug from the blood sample 
reaches the gut of the mosquito .177
Gametocyte developmen t goes through ﬁve stages of matura- 
tion, with stage V being the only form which can infect mosquitoes 
(Scheme 1). For P. falciparum , these mature gametocyte s start to be 
present 12 days after disease symptoms, circulate on average for 
2.5–6.5 days, 178 and persist for up to 22 days. 179 Thus, circulating 
gametocyte s can sustain malaria transmission well after drug 
treatment has caused disease symptoms to disappea r. For the other 
Plasmodium parasites , mature gametocyte s appear much earlier, 
closer to 1 day after disease symptoms appear. This difference in 
biology represents an additional challenge when optimizing dosing 
regimens of transmission- blocking drugs in the clinic. 
Most currently approved anti-malar ial drugs, including ACTs, 
are only effective against blood stages and young gametocytes up 
to stage III and possibly stage IV of gametocyte maturation (stage
III can be observed at day 4–6 and IV is observed at day 7–9;
Scheme 1). This unfortunately does not result in complete clear- 
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Scheme 26. Cladosporin and NITD-731 inhibit liver stages with novel mechanisms 
of action. EC 50 values are reported for the drug-sensitive strains 3D7 and D10. treatments, for example, chloroquine 180 and sulfadoxine–pyri- 
methami ne, 181 were found to induce gametocytogenes is, thus 
potential ly contributing to increased numbers of transmis sions 
and increased rates of new infections. 182
The transmis sion-blocking potential of approved and clinical 
antimala rials has been reviewed. 9,183,184 Currently, the only fully 
effective gametocytocidal drug is primaquine (10, Scheme 3),
which acts against gametocyte s of all malaria species and repre- 
sents the WHO recommended treatment option against P. falcipa- 
rum gametocyte s. Until recently, the WHO recomme ndation was 
a single primaquine dose of 0.75 mg/kg, 185 provided that the risk 
for acute hemolytic anemia (G6PD deﬁciency) had been evaluated 
prior to treatment. In 2012, the WHO recommend ed that the dose 
be lowered to 0.25 mg/kg, which is still effective at lowering trans- 
mission while being unlikely to cause serious toxicity in subjects 
with G6PD variants. 186,187 Thus, a single dose of primaquine 
(0.25 mg base/kg) should be given to all patients with parasitolog- 
ically-con ﬁrmed P. falciparum malaria on the ﬁrst day of treatment 
in addition to an ACT, except for pregnant women and infants 
<1 year of age. 186
Because of the risks associated with primaquine, novel trans- 
mission-block ing drugs are being sought for achieving the goal of 
global malaria eradication. Large strides have recently been made 
in understand ing the speciﬁcs of transmission-s tage biology, and 
in developing in vitro assays focused on late-stage gametocyte 
developmen t, lethality of mature gametocytes and the gameto- 
cyte–ookinete/sporozoite transition. 188–192
Tafenoqui ne (84), NITD609 (52),94 and GNF156 (88) were 
shown to have transmission- blocking activities in vitro. Tafenoqu- 
ine was also found to delay sporozoite formation in P. vivax . Inter- 
estingly, a recently developed gametocyte drug screening assay 
identiﬁed methylene blue (97, Scheme 27 ), as a potent inhibitor 
of gametocyte developmen t across all stages. Methylene blue is 
an approved injectabl e monoami ne oxidase inhibitor 193 for methe- 
moglobin emia, which almost fully abolishes P. falciparum trans-
mission to mosquito es at concentrations readily achievable in 
humans, highlighting the potential of this chemical class to reduce 
the spread of malaria. 194 Incidental ly, methylene blue was the ﬁrst
antimala rial to be tested in man (1891), based on Ehrlich’s obser- 
vation that it could stain the malaria parasite. 
Addition al examples of compound s with transmission- blocking 
activities include, amongst others, trioxaquine DU1302 (98,
Scheme 27 ), epoxomicin (99, nonselective over human cells),189
HIV protease inhibitors such as tipranavir (100),184,195 kinase
inhibitor BKI1 (101),196 ketotifen (102),197,198 thiostrepton
(103),195 and cycloheximi de (104).199
Anti-mal arial strategie s are ideally a balanced use of mosquito 
control, anti- Plasmodiu m treatments, and a general improvement 
of sanitation and awareness. 175,176 This is how malaria was eradi- 
cated from developed countries. Vaccines would also be extremely 
useful.200 Nonetheless , there is an urgent need for developing new 
anti-malaria l drugs. The new drugs can target the blood stage of 
the disease to alleviate the symptom s, the liver stage to prevent re- 
lapses, and the transmission stage to protect other humans. 
The pipeline for the blood stage is arguably the best in his- 
tory, but still needs to be expanded. The last few years have 
seen an explosion of potent new chemotypes, and the new chal- 
lenge is to assess the potential of these chemotypes. Ideally, the 
new drug should: (i) address drug-resistanc e issues, (ii) have a
rapid onset of action, (iii) be safe, especially in children and 
pregnant women, and (iv) cure malaria in a single dose. The 
challenge is to ﬁnd a drug that addresses all of these features. 
It is our hope that with the rich variety of new chemical entities, 
such a drug will be discovered. Neverthel ess, drug discovery ef- 
forts should continue, as the artemisinins set a high standard of 








































































































Scheme 27. Compounds with transmission blocking properties. 
2840 M. A. Biamonte et al. / Bioorg. Med. Chem. Lett. 23 (2013) 2829–2843Drugs that target the liver and transmission stages have the po- 
tential to be transformation al, but research efforts have been ham- 
pered by the absence of high-throughput screens. New imaging 
techniques are beginning to solve this problem and open up novel 
avenues, with an innovative clinical compound having liver stage 
activity. The ﬁeld of transmission-bl ocking agents is in its infancy, 
but may be the most transformat ive of all in achieving the ultimate 
goal of eradicating malaria. Acknowled gements 
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